Effect of single doses of IV palonosetron, up to 2.25 mg, on the QTc interval duration: a double-blind, randomized, parallel group study in healthy volunteers.

Autor: Morganroth J; eResearchTechnology Inc., Philadelphia, PA, USA., Flaharty KK; KF Consulting LLC, Fort Myers, FL, USA., Parisi S; Helsinn Healthcare SA, Lugano, Switzerland. Simona.Parisi@helsinn.com., Moresino C; Helsinn Healthcare SA, Lugano, Switzerland.

Publikováno v: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2016 Feb; Vol. 24 (2), pp. 621-627. Date of Electronic Publication: 2015 Jun 26.

Latisse (bimatoprost) for enhancement of eyelashes.

Autor: Flaharty PM, Flaharty KK, Gorman L

Publikováno v: Insight (American Society of Ophthalmic Registered Nurses) [Insight] 2014 Summer; Vol. 39 (3), pp. 24-6.

Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration.

Autor: Besarab A; Department of Medicine, Jefferson Medical College, Philadelphia, PA., Flaharty KK, Erslev AJ, McCrea JB, Vlasses PH, Medina F, Caro J, Morris E

Publikováno v: Journal of the American Society of Nephrology : JASN [J Am Soc Nephrol] 1992 Mar; Vol. 2 (9), pp. 1405-16.

Erythropoietin life span in rats with hypoplastic and hyperplastic bone marrows.

Autor: Piroso E; Cardeza Foundation for Hematologic Research Department of Internal Medicine, Philadelphia, PA 19107., Erslev AJ, Flaharty KK, Caro J

Publikováno v: American journal of hematology [Am J Hematol] 1991 Feb; Vol. 36 (2), pp. 105-10.

Clinical pharmacology of recombinant human erythropoietin (r-HuEPO).

Autor: Flaharty KK; Department of Medicine, Jefferson Medical College, Philadelphia, Pennsylvania 19107-5563.

Publikováno v: Pharmacotherapy [Pharmacotherapy] 1990 Mar-Apr; Vol. 10 (2 ( Pt 2)), pp. 9S-14S.